Efficacy of early administration of sacubitril/valsartan after coronary artery revascularization in patients with acute myocardial infarction complicated by moderate-to-severe mitral regurgitation: a randomized controlled trial

• Published in: Heart and vessels Vol. 39; no. 8; pp. 673 - 686
• Main Authors: Yin, Hongtao, Ma, Lixiang, Zhou, Yanqing, Tang, Xiuying, Li, Runjun, Zhou, Yingjun, Shi, Jiaxiu, Zhang, Jun
• Format: Journal Article
• Language: English
• Published: Tokyo Springer Japan 01.08.2024; Springer Nature B.V
• Subjects: Aged; Aminobutyrates - administration & dosage; Aminobutyrates - adverse effects; Aminobutyrates - therapeutic use; Angina; Angioedema; Angiotensin; Angiotensin Receptor Antagonists - administration & dosage; Angiotensin Receptor Antagonists - therapeutic use; Angiotensin-converting enzyme inhibitors; Biomedical Engineering and Bioengineering; Biphenyl Compounds; Brain natriuretic peptide; Cardiac Surgery; Cardiology; Cerebral infarction; Congestive heart failure; Coronary artery; Coronary vessels; Cough; Drug Combinations; Effectiveness; Ejection fraction; Enzyme inhibitors; Female; Heart attacks; Heart failure; Heart rate; Hospitalization; Humans; Hyperkalemia; Hypotension; Male; Medicine; Medicine & Public Health; Middle Aged; Mitral Valve Insufficiency - complications; Mitral Valve Insufficiency - diagnosis; Mitral Valve Insufficiency - physiopathology; Mitral Valve Insufficiency - surgery; Myocardial infarction; Myocardial Infarction - complications; Neprilysin; Original Article; Patients; Peptidyl-dipeptidase A; Percutaneous Coronary Intervention - methods; Regurgitation; Renal function; Safety; Severity of Illness Index; Single-Blind Method; Stroke Volume - physiology; Time Factors; Treatment Outcome; Valsartan - administration & dosage; Valsartan - adverse effects; Vascular Surgery; Veins & arteries; Ventricle; Ventricular Function, Left - drug effects; Ventricular Function, Left - physiology; Ventricular Remodeling - drug effects; Ventricular Remodeling - physiology; Mitral regurgitation; Sacubitril/valsartan; Angiotensin receptor/neprilysin inhibitors; Ventricular remodeling; Acute myocardial infarction
• ISSN: 0910-8327; 1615-2573; 1615-2573
• DOI: 10.1007/s00380-024-02398-2

Effects of angiotensin receptor/neprilysin inhibitors (ARNI) on ventricular remodeling in patients with heart failure, especially heart failure with reduced ejection fraction (HFrEF), are better than those of angiotensin-converting enzyme inhibitors (ACEI). Acute myocardial infarction (AMI) complicated by mitral regurgitation exacerbates ventricular remodeling and increases the risk of heart failure. There is limited evidence on the effects of early administration of ARNI in patients with AMI complicated by mitral regurgitation. The aim of this trial was to examine the effectiveness and the safety of early administration of sacubitril/valsartan after coronary artery revascularization in patients with AMI complicated by moderate-to-severe mitral regurgitation. This was a randomized, single-blind, parallel-group, controlled trial. From June 2021 to June 2022, we enrolled 142 consecutive patients with AMI complicated by moderate-to-severe mitral regurgitation and followed them for 12 months. The patients received standard treatment for AMI and were randomly assigned to receive ARNI or benazepril. The primary efficacy end points were the differences in mitral regurgitant jet area (MRJA), mitral regurgitant volume (MRV), concentration of n-terminal pro-brain natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), and left ventricular end-diastolic volume and end-systolic volume (LVEDV and LVESV) between groups and within groups at baseline, 1, 3, 6, and 12 months. Secondary end points included the rates of heart failure hospitalization, all-cause mortality, refractory angina, malignant arrhythmias, recurrent myocardial infarction, and stroke. Safety end points included the rates of hyperkalemia, renal dysfunction, hypotension, angioedema, and cough. The ARNI group had significantly lower NT-proBNP levels than the benazepril group at 1 month and later ( P  < 0.001). MRJA and MRV significantly improved in the ARNI group compared with the benazepril group at 12 months (MRJA: − 3.21 ± 2.18 cm 2 vs. − 1.83 ± 2.81 cm 2 , P  < 0.05; MRV: − 27.22 ± 15.22 mL vs. − 13.67 ± 21.02 mL, P  < 0.001). The ARNI group also showed significant reductions in LVEDV and LVESV ( P  < 0.05) and improvement in LVEF (P < 0.05). Secondary end point analysis showed a significantly higher rate of heart failure hospitalization in the benazepril group compared with the ARNI group (HR = 2.03, 95% CI 1.12–3.68, P  = 0.021). Safety end point analysis showed a higher rate of hypotension in the ARNI group ( P  < 0.05). Early use of sacubitril/valsartan after coronary artery revascularization in patients with AMI complicated by moderate-to-severe mitral regurgitation can significantly reduce mitral regurgitation, improve ventricular remodeling, and decrease heart failure hospitalization. Nevertheless, caution is needed to avoid hypotension. Chinese Clinical Trial Registry (ChiCTR2100054255) registered on December 11, 2021.